B 9870
Alternative Names: CU 201Latest Information Update: 12 Jun 2007
At a glance
- Originator Nonindustrial source
- Class Antineoplastics
- Mechanism of Action Bradykinin B1 receptor antagonists; Bradykinin B2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer